Randomised-controlled trial of a fibre supplement on the symptoms of irritable bowel syndrome - PubMed (original) (raw)

Clinical Trial

Randomised-controlled trial of a fibre supplement on the symptoms of irritable bowel syndrome

Gail Rees et al. J R Soc Promot Health. 2005 Jan.

Abstract

The aim of this study was to assess the effect of coarse wheat bran on specific bowel function parameters and symptoms in patients with irritable bowel syndrome (IBS). A longitudinal, prospective, randomised, placebo-controlled trial was undertaken. The duration of treatment was eight to 12 weeks and this consisted of 10-20 g/day of coarse wheat bran or a low fibre placebo taken in addition to the normal diet. Twenty-eight outpatients fulfilling the Rome criteria for constipation-predominant IBS were recruited to the trial (14 in the treatment group; 14 in the placebo group). Twelve people completed the trial in the treatment group and ten in the placebo group. The main outcome measures included changes in symptoms recorded in a diary, changes in objective measurements of bowel function and subjective overall feelings of improvement. The bran group significantly increased their non-starch polysaccharide (NSP) intake over that of the placebo group (p < 0.05). Mean stool wet weight increased significantly more in the bran group than in the placebo group (p < 0.05), but other bowel function measurements and all recorded symptoms were not different. Many patients reported changes in bowel habit that were not reflected in the objective measurements. The addition of coarse wheat bran to the diet increased NSP ingestion and stool wet weight in this group of IBS patients, but no evidence was obtained that such treatment was of benefit to these patients, other than a placebo effect on symptoms.

PubMed Disclaimer

Cited by

The Role of Dietary Fibers in the Management of IBD Symptoms.
Di Rosa C, Altomare A, Imperia E, Spiezia C, Khazrai YM, Guarino MPL. Di Rosa C, et al. Nutrients. 2022 Nov 11;14(22):4775. doi: 10.3390/nu14224775. Nutrients. 2022. PMID: 36432460 Free PMC article. Review.
Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial.
Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Bijkerk CJ, et al. BMJ. 2009 Aug 27;339:b3154. doi: 10.1136/bmj.b3154. BMJ. 2009. PMID: 19713235 Free PMC article. Clinical Trial.
Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.
Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Ruepert L, et al. Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD003460. doi: 10.1002/14651858.CD003460.pub3. Cochrane Database Syst Rev. 2011. PMID: 21833945 Free PMC article. Review.
Guidelines on the management of irritable bowel syndrome: In memory of Professor Witold Bartnik.
Pietrzak A, Skrzydło-Radomańska B, Mulak A, Lipiński M, Małecka-Panas E, Reguła J, Rydzewska G. Pietrzak A, et al. Prz Gastroenterol. 2018;13(4):259-288. doi: 10.5114/pg.2018.78343. Epub 2018 Sep 19. Prz Gastroenterol. 2018. PMID: 30581501 Free PMC article.
Constipation-Predominant Irritable Bowel Syndrome (IBS-C): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms.
Di Rosa C, Altomare A, Terrigno V, Carbone F, Tack J, Cicala M, Guarino MPL. Di Rosa C, et al. Nutrients. 2023 Mar 28;15(7):1647. doi: 10.3390/nu15071647. Nutrients. 2023. PMID: 37049488 Free PMC article. Review.

Randomised-controlled trial of a fibre supplement on the symptoms of irritable bowel syndrome - PubMed (original) (raw)